...
首页> 外文期刊>Medicine. >Gender-related efficacy of pulmonary surfactant in infants with respiratory distress syndrome: A STROBE compliant study
【24h】

Gender-related efficacy of pulmonary surfactant in infants with respiratory distress syndrome: A STROBE compliant study

机译:肺表面活性物质对呼吸窘迫综合征婴儿的性别相关功效:一项符合STROBE的研究

获取原文
           

摘要

Whether gender influences the efficacy of exogenous pulmonary surfactant (PS) for replacement therapy in newborns with respiratory distress syndrome (RDS) has not been well studied yet. Retrospective cohort study design. Data on PS therapy including blood gas, oxygenation function parameters, and therapy results were collected and analyzed from 370 infants diagnosed with RDS in 20 hospitals of the Northwest China Neonatal Collaboration from January 2011 to December 2011. Female infants were more sensitive to PS treatment than males. In multivariate analysis, when adjusted for other variables, an increased initial dose of surfactant significantly reduced mortality risk (OR = 0.98, 95%CI [0.96, 0.99], P = .002). An interaction between gender and initial dose of PS was observed. In male infants , an increased initial dose of surfactant was correlated with reduced mortality risk (OR = 0.97, 95%CI [0.96, 0.99], P = 0.005), while in female infants , we failed to found a relationship between the initial dose of surfactant and the risk of mortality (OR = 0.99, 95%CI [0.96, 1.02], P = .543). Moreover, the effect of surfactant replacement therapy was better for female infants than male infants at initial PS doses <130 mg/kg. Gender influences the efficacy of PS treatment. An increased initial dose of PS should be used in RDS therapy for male infants .
机译:性别是否会影响呼吸窘迫综合征(RDS)新生儿的外源性肺表面活性物质(PS)替代疗法的功效尚未得到很好的研究。回顾性队列研究设计。收集并分析了2011年1月至2011年12月在西北地区20家新生儿协作医院的370例诊断为RDS的婴儿中PS疗法的数据,包括血气,氧合功能参数和治疗结果。男性。在多变量分析中,当调整其他变量后,增加表面活性剂的初始剂量可以显着降低死亡风险(OR = 0.98,95%CI [0.96,0.99],P = .002)。观察到性别与PS初始剂量之间存在相互作用。在男婴中,增加表面活性剂的初始剂量与降低死亡风险相关(OR = 0.97,95%CI [0.96,0.99],P = 0.005),而在女婴中,我们未能发现初始剂量之间的关系表面活性剂的使用和死亡风险(OR = 0.99,95%CI [0.96,1.02],P = .543)。此外,在初始PS剂量<130 mg / kg时,表面活性剂替代疗法对女婴的效果要好于对男婴。性别影响PS治疗的功效。对于男性婴儿,RDS治疗中应该使用增加的PS初始剂量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号